home / stock / fwbi / fwbi news

FWBI News and Press, First Wave BioPharma Inc. From 03/14/23

Stock Information
Company Name: First Wave BioPharma Inc.
Stock Symbol: FWBI
Market: NASDAQ
Menu
FWBI FWBI Quote FWBI Short FWBI News FWBI Articles FWBI Message Board
Get FWBI Alerts

News, Short Squeeze, Breakout and More Instantly...
FWBI - PaxMedica, Avid Bioservices top healthcare gainers; Rapt, Unicycive lead losers' pack

2023-03-14 10:08:44 ET Gainers: PaxMedica ( PXMD ) +36% . Avid Bioservices ( CDMO ) +25% . Amylyx Pharmaceuticals ( AMLX ) +17% . Euda Health ( EUDA ) +17% .  Addex Therapeutics ( ADXN ) +11% . Losers: Rapt Therap...
FWBI - First Wave BioPharma launches $4M securities offering

2023-03-13 08:12:36 ET First Wave BioPharma ( NASDAQ: FWBI ) has launched a $4M private offering of stocks and warrants. The offering comprises 1,023,018 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,046,036 shares of comm...

FWBI - First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases...

FWBI - HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Commi...
FWBI - First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

BOCA RATON, Fla., March 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointest...

FWBI - First Wave stock surges ~15% as dosing starts in pancreas disorder trial

2023-03-09 09:25:44 ET First Wave BioPharma ( NASDAQ: FWBI ) said the first patient was dosed in phase 2 trial of an enhanced enteric microgranule delivery formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). EPI...

FWBI - FIGS, FWBI and ATXI among pre market gainers

2023-03-09 08:40:39 ET Ocean Biomedical ( OCEA ) +38% on sharing detailed research data on anti-tumor pathway discoveries and their potential for treatment of non-small cell lung cancer, metastatic melanoma, and glioblastoma by scientific co-founder. First Wave ( FWB...
FWBI - First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

BOCA RATON, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointest...

FWBI - First Wave BioPharma to Participate in 'Fireside Chat' at the 35th Annual Roth Conference

BOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...

FWBI - First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference

BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...
Previous 10 Next 10